PFE · 8-K · 20260804PR000094

COVID Product Demand Decline

PFIZER INC · 2026-08-04 · Importance 57 · Surprise 64 · From source text

COVID-19 product demand weakened materially during the quarter. Paxlovid revenue declined 95% operationally globally, driven by lower COVID-19 infections across U.S. and international markets and lower government purchases in certain international markets. Comirnaty revenue declined 34% operationally, reflecting a lower favorable adjustment to the returns provision and lower U.S. utilization associated with a narrower vaccination recommendation. Pfizer revised its 2026 COVID-19 product revenue expectation to approximately $4 billion from approximately $5 billion previously.

Key facts

• Revised 2026 revenue expectation for COVID-19 products: down to approximately $4 billion from approximately $5 billion previously source
• Comirnaty revenues in Second-Quarter 2026: $261 million, down 32% (or down 34% operational) versus 2025; U.S. $38 million, down 79%; International $223 million, up 9% source
• Comirnaty revenues for Six Months 2026: $493 million, down 48% (or 49% operational) versus Six Months 2025; U.S. $169 million, down 58%; International $324 million, down 40% source
• Paxlovid revenues in Second-Quarter 2026: $21 million, down 95% (or 95% operational) versus 2025; U.S. $0 million, down 100%; International $20 million, down 80% source
• Paxlovid revenues for Six Months 2026: $207 million, down 77% (or 78% operational) versus Six Months 2025; U.S. $136 million, down 80%; International $71 million, down 71% source
• Paxlovid global operational decline: down 95% in Q2 2026 source
• Comirnaty global operational decline: down 34% in Q2 2026 source
• Excluding contributions from Comirnaty and Paxlovid, second-quarter revenues grew 5% operationally source

Impact estimates